These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8170559)

  • 1. The sorbinil retinopathy trial: neuropathy results. Sorbinil Retinopathy Trial Research Group.
    Neurology; 1993 Jun; 43(6):1141-9. PubMed ID: 8170559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil.
    O'Hare JP; Morgan MH; Alden P; Chissel S; O'Brien IA; Corrall RJ
    Diabet Med; 1988 Sep; 5(6):537-42. PubMed ID: 2974776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials of sorbinil on nerve function.
    Pfeifer MA
    Metabolism; 1986 Apr; 35(4 Suppl 1):78-82. PubMed ID: 3083211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.
    Jaspan JB; Towle VL; Maselli R; Herold K
    Metabolism; 1986 Apr; 35(4 Suppl 1):83-92. PubMed ID: 3083212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy.
    Jaspan JB; Herold K; Bartkus C
    Am J Med; 1985 Nov; 79(5A):24-37. PubMed ID: 3000176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glycemic control and aldose reductase inhibition on nerve conduction velocity.
    Pfeifer MA
    Am J Med; 1985 Nov; 79(5A):18-23. PubMed ID: 3934964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group.
    Arch Ophthalmol; 1990 Sep; 108(9):1234-44. PubMed ID: 2119168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in peripheral nerve function after one year of Sorbinil.
    Gieron MA; Malone JI; Lowitt S; Korthals JK
    Neuroreport; 1991 Jun; 2(6):348-50. PubMed ID: 1655107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy.
    Lewin IG; O'Brien IA; Morgan MH; Corrall RJ
    Diabetologia; 1984 Jun; 26(6):445-8. PubMed ID: 6432615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients.
    Judzewitsch RG; Jaspan JB; Polonsky KS; Weinberg CR; Halter JB; Halar E; Pfeifer MA; Vukadinovic C; Bernstein L; Schneider M; Liang KY; Gabbay KH; Rubenstein AH; Porte D
    N Engl J Med; 1983 Jan; 308(3):119-25. PubMed ID: 6401351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of an aldose reductase inhibitor (Sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study.
    Christensen JE; Varnek L; Gregersen G
    Acta Neurol Scand; 1985 Feb; 71(2):164-7. PubMed ID: 3920861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldose reductase inhibitors and late complications of diabetes.
    Benfield P
    Drugs; 1986; 32 Suppl 2():43-55. PubMed ID: 3098544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial.
    Fagius J; Brattberg A; Jameson S; Berne C
    Diabetologia; 1985 Jun; 28(6):323-9. PubMed ID: 3930330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity.
    Sima AA; Prashar A; Nathaniel V; Bril V; Werb MR; Greene DA
    Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldose reductase inhibitors in clinical practice. Preliminary studies on diabetic neuropathy and retinopathy.
    Pitts NE; Gundersen K; Mehta DJ; Vreeland F; Shaw GL; Peterson MJ; Collier J
    Drugs; 1986; 32 Suppl 2():30-5. PubMed ID: 3098543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)].
    Christensen JE; Larsen AB; Gregersen G
    Ugeskr Laeger; 1987 Nov; 149(46):3111-4. PubMed ID: 3127975
    [No Abstract]   [Full Text] [Related]  

  • 17. Prolonged aldose reductase inhibition in chronic peripheral diabetic neuropathy: effects on microangiopathy.
    Jennings PE; Nightingale S; Le Guen C; Lawson N; Williamson JR; Hoffman P; Barnett AH
    Diabet Med; 1990 Jan; 7(1):63-8. PubMed ID: 2137066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibition of aldose reductase in human diabetic neuropathy.
    Jaspan J
    Drugs; 1986; 32 Suppl 2():23-9. PubMed ID: 2431859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.
    Sima AA; Bril V; Nathaniel V; McEwen TA; Brown MB; Lattimer SA; Greene DA
    N Engl J Med; 1988 Sep; 319(9):548-55. PubMed ID: 3136331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.